A detailed history of De Dora Capital, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, De Dora Capital, Inc. holds 3,213 shares of GILD stock, worth $283,001. This represents 0.08% of its overall portfolio holdings.

Number of Shares
3,213
Previous 7,015 54.2%
Holding current value
$283,001
Previous $481,000 44.07%
% of portfolio
0.08%
Previous 0.15%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

SELL
$66.59 - $83.99 $253,175 - $319,329
-3,802 Reduced 54.2%
3,213 $269,000
Q2 2024

Jul 17, 2024

SELL
$63.15 - $72.88 $9,851 - $11,369
-156 Reduced 2.18%
7,015 $481,000
Q1 2024

Apr 16, 2024

SELL
$71.58 - $87.29 $214,883 - $262,044
-3,002 Reduced 29.51%
7,171 $525,000
Q4 2023

Jan 18, 2024

BUY
$73.27 - $83.09 $4,322 - $4,902
59 Added 0.58%
10,173 $824,000
Q3 2023

Oct 18, 2023

BUY
$73.94 - $80.67 $86,509 - $94,383
1,170 Added 13.08%
10,114 $757,000
Q2 2023

Jul 24, 2023

BUY
$76.01 - $86.7 $19,078 - $21,761
251 Added 2.89%
8,944 $689,000
Q1 2023

May 11, 2023

BUY
$77.31 - $88.08 $1,778 - $2,025
23 Added 0.27%
8,693 $721,000
Q4 2022

Jan 18, 2023

BUY
$62.32 - $89.47 $32,468 - $46,613
521 Added 6.39%
8,670 $0
Q3 2022

Oct 14, 2022

SELL
$59.54 - $68.01 $13,396 - $15,302
-225 Reduced 2.69%
8,149 $503,000
Q2 2022

Jul 27, 2022

SELL
$57.72 - $65.01 $512,149 - $576,833
-8,873 Reduced 51.45%
8,374 $518,000
Q1 2022

Apr 14, 2022

BUY
$57.92 - $72.58 $998,946 - $1.25 Million
17,247 New
17,247 $1.03 Million
Q4 2021

Jan 18, 2022

SELL
$64.88 - $73.64 $976,054 - $1.11 Million
-15,044 Closed
0 $0
Q3 2021

Oct 18, 2021

BUY
$67.69 - $73.03 $23,353 - $25,195
345 Added 2.35%
15,044 $1.05 Million
Q2 2021

Aug 03, 2021

SELL
$63.47 - $69.35 $4,569 - $4,993
-72 Reduced 0.49%
14,699 $1.01 Million
Q1 2021

Apr 27, 2021

BUY
$60.0 - $68.46 $7,920 - $9,036
132 Added 0.9%
14,771 $955,000
Q4 2020

Jan 29, 2021

SELL
$56.65 - $64.55 $40,051 - $45,636
-707 Reduced 4.61%
14,639 $853,000
Q3 2020

Oct 20, 2020

BUY
$62.1 - $78.08 $116,748 - $146,790
1,880 Added 13.96%
15,346 $970,000
Q2 2020

Jul 31, 2020

BUY
$72.34 - $84.0 $62,140 - $72,156
859 Added 6.81%
13,466 $1.04 Million
Q1 2020

May 04, 2020

SELL
$62.63 - $80.22 $15,532 - $19,894
-248 Reduced 1.93%
12,607 $942,000
Q4 2019

Feb 21, 2020

BUY
$61.62 - $67.78 $45,290 - $49,818
735 Added 6.06%
12,855 $835,000
Q3 2019

Oct 22, 2019

SELL
$62.51 - $69.0 $189,342 - $209,001
-3,029 Reduced 19.99%
12,120 $768,000
Q2 2019

Aug 08, 2019

BUY
$61.87 - $69.38 $31,986 - $35,869
517 Added 3.53%
15,149 $1.02 Million
Q1 2019

Apr 12, 2019

BUY
$62.53 - $70.05 $210,726 - $236,068
3,370 Added 29.92%
14,632 $951,000
Q4 2018

Jan 18, 2019

BUY
$60.54 - $79.0 $337,389 - $440,267
5,573 Added 97.96%
11,262 $704,000
Q3 2018

Oct 19, 2018

SELL
$71.28 - $78.92 $71,137 - $78,762
-998 Reduced 14.92%
5,689 $439,000
Q2 2018

Jul 31, 2018

SELL
$64.88 - $75.68 $24,589 - $28,682
-379 Reduced 5.36%
6,687 $474,000
Q1 2018

Apr 16, 2018

SELL
$72.84 - $88.8 $21,342 - $26,018
-293 Reduced 3.98%
7,066 $533,000
Q4 2017

Feb 09, 2018

BUY
$71.15 - $83.52 $523,592 - $614,623
7,359
7,359 $527,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track De Dora Capital, Inc. Portfolio

Follow De Dora Capital, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of De Dora Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on De Dora Capital, Inc. with notifications on news.